Valuation: Assembly Biosciences, Inc.

Capitalization 129M 112M 104M 94.93M 175M 11.08B 198M 1.22B 475M 5.07B 483M 473M 18.59B P/E ratio 2025 *
-4.75x
P/E ratio 2026 * -7.59x
Enterprise value 129M 112M 104M 94.93M 175M 11.08B 198M 1.22B 475M 5.07B 483M 473M 18.59B EV / Sales 2025 *
5.13x
EV / Sales 2026 * 6.25x
Free-Float
67.89%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.46%
1 week+3.76%
Current month+19.08%
1 month+39.14%
3 months+55.16%
6 months+9.56%
Current year+6.78%
More quotes
1 week 15.54
Extreme 15.54
17.43
1 month 12.76
Extreme 12.7619
17.43
Current year 7.75
Extreme 7.75
18.05
1 year 7.75
Extreme 7.75
19.93
3 years 7.69
Extreme 7.692
29.04
5 years 7.69
Extreme 7.692
334.08
10 years 7.69
Extreme 7.692
808.32
More quotes
Manager TitleAgeSince
Chief Executive Officer 49 2022-12-31
Director of Finance/CFO - 2025-06-04
Chief Tech/Sci/R&D Officer 47 2023-11-07
Director TitleAgeSince
Director/Board Member 69 2011-12-31
Chairman 79 2015-02-09
Director/Board Member 60 2017-12-13
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.46%+3.76%+9.49%-27.25% 129M
-2.50%-0.80%+18.43%+13.26% 49.5B
-1.41%+3.00%-26.26%-21.90% 27.14B
-1.89%+2.53%-4.26%+17.06% 26.06B
-0.17%+3.36%+15.73%-22.51% 12.53B
+0.07%+14.84%+77.09% - 12.34B
-0.97%+4.71%-53.51%-28.71% 11.57B
-2.49%-2.88%-80.95%-78.06% 10.31B
-0.07%-1.31%+33.81%+110.24% 10.31B
-0.59%+3.58%+8.18%+3.37% 10.2B
Average -1.15%+2.86%-0.23%-3.83% 17.01B
Weighted average by Cap. -1.51%+1.91%+1.27%+1.62%
See all sector performances

Financials

2025 *2026 *
Net sales 25.1M 21.75M 20.37M 18.52M 34.1M 2.16B 38.71M 238M 92.76M 988M 94.22M 92.19M 3.63B 20.58M 17.84M 16.7M 15.18M 27.95M 1.77B 31.73M 195M 76.05M 810M 77.25M 75.58M 2.97B
Net income -33.76M -29.25M -27.39M -24.9M -45.85M -2.91B -52.05M -320M -125M -1.33B -127M -124M -4.88B -34.54M -29.93M -28.02M -25.48M -46.91M -2.97B -53.25M -328M -128M -1.36B -130M -127M -4.99B
Net Debt - -
More financial data * Estimated data
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Employees
73
More about the company
Date Price Change Volume
25-06-13 16.85 $ -1.46% 40,784
25-06-12 17.10 $ +0.29% 17,196
25-06-11 17.05 $ -1.16% 9,165
25-06-10 17.25 $ +7.34% 59,102
25-06-09 16.07 $ -1.05% 23,075

Delayed Quote Nasdaq, June 13, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.85USD
Average target price
30.00USD
Spread / Average Target
+78.04%
Consensus

Quarterly revenue - Rate of surprise